Paroxetine controlled-release formulation in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled study in Japan and Korea

Psychiatry and Clinical Neurosciences

Volumn 65, Issue 7, 2011, Pages 655-663

  Higuchi, Teruhiko ^a   Hong, Jin Pyo ^c   Jung, Hee Yeon ^c   Watanabe, Yoshinori ^a   Kunitomi, Taro ^a   Kamijima, Kunitoshi ^b  

^a Development and Medical Affairs Division   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c Seoul National University   (South Korea)

Author keywords

Japan; Korea; major depressive disorder; paroxetine; placebo

Indexed keywords

PAROXETINE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION DISORDER; FEMALE; FEVER; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; JAPAN; KOREA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MULTICENTER STUDY; NAUSEA; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SWEATING; THIRST; TREMOR; XEROSTOMIA;

ADULT; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PAROXETINE; REPUBLIC OF KOREA; SEROTONIN UPTAKE INHIBITORS;

EID: 84255214073     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2011.02243.x     Document Type: Article

References (14)

1. American Psychiatric Association. Practice Guidelines for the Treatment of Psychiatric Disorders. American Psychiatric Association, Washington, DC, 2004.
2. Lin EHB, VonKorff M, Katon W, et al,. The role of the primary care physician in patients' adherence to antidepressant therapy. Med. Care 1995; 33: 67-74.
3. Pae CU, Bahk WM, Jon DI, et al,. Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea. Hum. Psychopharmacol. 2007; 22: 351-359.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn., text revision. American Psychiatric Association, Washington, DC, 2000.
5. Hamilton M,. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 56-62.
6. Nakane Y,. Japanese Version of Structured Interview Guide for the Hamilton Depression Rating Scale. Seiwa Shoten, Tokyo, 2003.
7. Williams JB,. A structured interview guide for the Hamilton Depression Rating Scale. Arch. Gen. Psychiatry 1988; 45: 742-747.
8. Judge R, Parry MG, Quail D, Jacobson JG,. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int. Clin. Psychopharmacol. 2002; 17: 217-225.
9. Black K, Shea C, Dursun S, Kutcher S,. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J. Psychiatry Neurosci. 2000; 25: 255-261. (Pubitemid 30641002)
10. Haddad PM,. Antidepressant discontinuation syndromes. Drug Saf. 2001; 24: 183-197.
11. Golden RN, Nemeroff CB, McSorley P, et al,. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J. Clin. Psychiatry 2002; 63: 577-584. (Pubitemid 34787322)
12. Himei A, Okamura T,. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 2006; 20: 665-672. (Pubitemid 44141493)
13. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I,. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int. Clin. Psychopharmacol. 2006; 21: 159-169. (Pubitemid 43740307)
14. Montgomery SA, Fava M, Padmanabhan SK, et al,. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int. Clin. Psychopharmacol. 2009; 24: 296-305.